{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:42:39Z","timestamp":1793310159181,"version":"4.5.0"},"reference-count":75,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Brittle Bone Disease Consortium","award":["#1U54AR068069\u20130"],"award-info":[{"award-number":["#1U54AR068069\u20130"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Osteogenesis imperfecta (OI) is a genetic disorder characterized by increased bone fragility largely caused by defects in structure, synthesis, or post-translational processing of type I collagen. The effectiveness of medications used for fracture reduction in adults with OI is understudied and practice recommendations are not well established. Drugs currently used to improve skeletal health in OI were initially developed to treat osteoporosis. Oral and intravenous bisphosphonates have been shown to improve bone mineral density (BMD) in adults with OI and are commonly used; however, conclusive data confirming fracture protection are lacking. Similarly, teriparatide appears to increase BMD, an effect that seems to be limited to individuals with type I OI. The role of denosumab, abaloparatide, romosozumab, and estradiol\/testosterone in adult OI have not been systematically studied. Anti-sclerostin agents and transforming growth factor-beta antagonists are under investigation in clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This review summarizes current knowledge on pharmacologic treatment options for reducing fracture risk in adults with OI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A PubMed online database search of all study types published in the English language using the terms \u201costeogenesis imperfecta,\u201d \u201cOI,\u201d and \u201cbrittle bone disease\u201d was performed in June 2022. Articles screened were restricted to adults. Additional sources were identified through manual searches of reference lists.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Fracture rates are elevated in adults with OI. Although clinical trial data are limited, bisphosphonates and teriparatide may be useful in improving BMD. Further research is needed to develop medications for adults with OI that will lead to definite fracture rate reduction.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad035","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T05:27:51Z","timestamp":1674192471000},"page":"1787-1796","source":"Crossref","is-referenced-by-count":44,"title":["Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2607-0336","authenticated-orcid":false,"given":"Winnie","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University , Portland, OR 97239 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Molecular and Human Genetics, Baylor College of Medicine , Houston, TX 77030 , USA"},{"name":"Texas Children's Hospital , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandesh C S","family":"Nagamani","sequence":"additional","affiliation":[{"name":"Department of Molecular and Human Genetics, Baylor College of Medicine , Houston, TX 77030 , USA"},{"name":"Texas Children's Hospital , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Nicol","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Endocrinology, Oregon Health & Science University , Portland, OR 97239 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rauch","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children , Montreal, Quebec H3G 1A6 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T","family":"Rush","sequence":"additional","affiliation":[{"name":"Children's Mercy Hospital, University of Missouri-Kansas City , Kansas City, MO 64108 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V Reid","family":"Sutton","sequence":"additional","affiliation":[{"name":"Department of Molecular and Human Genetics, Baylor College of Medicine , Houston, TX 77030 , USA"},{"name":"Texas Children's Hospital , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-7355","authenticated-orcid":false,"given":"Eric","family":"Orwoll","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University , Portland, OR 97239 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"issue":"10028","key":"2023061601040770500_dgad035-B1","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"2023061601040770500_dgad035-B2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1749-6632.2009.05317.x","article-title":"Genetics of osteoporosis","volume":"1192","author":"Ralston","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2023061601040770500_dgad035-B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2019.04.021","article-title":"Mendelian Bone fragility disorders","volume":"126","author":"Robinson","year":"2019","journal-title":"Bone"},{"issue":"7","key":"2023061601040770500_dgad035-B4","doi-asserted-by":"publisher","first-page":"e3048","DOI":"10.1210\/clinem\/dgac147","article-title":"Genetic diagnostics in routine osteological assessment of adult low bone mass disorders","volume":"107","author":"Oheim","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023061601040770500_dgad035-B5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1210\/endrev\/bnab017","article-title":"Osteogenesis imperfecta: mechanisms and signaling pathways connecting classical and rare OI types","volume":"43","author":"Jovanovic","year":"2022","journal-title":"Endocr Rev"},{"issue":"1","key":"2023061601040770500_dgad035-B6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00003086-199703000-00034","article-title":"Bone histomorphometry in adults with type IA osteogenesis imperfecta","volume":"336","author":"McCarthy","year":"1997","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"2023061601040770500_dgad035-B7","doi-asserted-by":"publisher","first-page":"100362","DOI":"10.1016\/j.ajogmf.2021.100362","article-title":"Pregnancy in women with osteogenesis imperfecta: pregnancy characteristics, maternal, and neonatal outcomes","volume":"3","author":"Rao","year":"2021","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"26","key":"2023061601040770500_dgad035-B8","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJM198406283102602","article-title":"Osteogenesis imperfecta after the menopause","volume":"310","author":"Paterson","year":"1984","journal-title":"N Engl J Med"},{"issue":"1","key":"2023061601040770500_dgad035-B9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jbmr.2920","article-title":"Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study","volume":"32","author":"Folkestad","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2023061601040770500_dgad035-B10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"issue":"4","key":"2023061601040770500_dgad035-B11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/jbmr.2835","article-title":"Bone material properties in osteogenesis Imperfecta","volume":"31","author":"Bishop","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023061601040770500_dgad035-B12","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1210\/jcem.85.5.6584","article-title":"Pamidronate treatment of severe osteogenesis Imperfecta in children under 3 years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"2023061601040770500_dgad035-B13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"issue":"9902","key":"2023061601040770500_dgad035-B14","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"2023061601040770500_dgad035-B15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1359\/jbmr.2003.18.4.610","article-title":"Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy","volume":"18","author":"Rauch","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023061601040770500_dgad035-B16","doi-asserted-by":"publisher","first-page":"e10118","DOI":"10.1002\/jbm4.10118","article-title":"A multicenter observational cohort study to evaluate the effects of bisphosphonate exposure on bone mineral density and other health outcomes in osteogenesis Imperfecta","volume":"3","author":"Bains","year":"2019","journal-title":"JBMR Plus"},{"issue":"3","key":"2023061601040770500_dgad035-B17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2106\/JBJS.L.01596","article-title":"Behavior of scoliosis during growth in children with osteogenesis imperfecta","volume":"96","author":"Anissipour","year":"2014","journal-title":"J Bone Joint Surg Am"},{"issue":"10","key":"2023061601040770500_dgad035-B18","doi-asserted-by":"publisher","first-page":"Cd005088","DOI":"10.1002\/14651858.CD005088.pub4","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2023061601040770500_dgad035-B19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023061601040770500_dgad035-B20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1359\/JBMR.051015","article-title":"Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial","volume":"21","author":"Chevrel","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023061601040770500_dgad035-B21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.endinu.2018.05.015","article-title":"Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up","volume":"66","author":"Pav\u00f3n de Paz","year":"2019","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"4","key":"2023061601040770500_dgad035-B22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-017-0236-9","article-title":"Long-term effects of neridronate in adults with osteogenesis imperfecta: an observational three-year Italian study","volume":"100","author":"Viapiana","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2023061601040770500_dgad035-B23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","article-title":"Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta","volume":"87","author":"Shapiro","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"2023061601040770500_dgad035-B24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.4158\/EP151184.OR","article-title":"The clinical characteristics and efficacy of bisphophonates in adult patients with osteogenesis imperfecta","volume":"22","author":"Xu","year":"2016","journal-title":"Endocr Pract"},{"key":"2023061601040770500_dgad035-B25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/B978-0-12-397165-4.00055-1","volume-title":"Osteogenesis Imperfecta: A Translational Approach to Brittle Bone Disease.","author":"Shapiro","year":"2014"},{"issue":"1","key":"2023061601040770500_dgad035-B26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00198-011-1658-2","article-title":"Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists","volume":"23","author":"Bradbury","year":"2012","journal-title":"Osteoporos Int"},{"issue":"5","key":"2023061601040770500_dgad035-B27","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"2023061601040770500_dgad035-B28","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis\u2014for whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2023061601040770500_dgad035-B29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.bone.2008.01.003","article-title":"Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis","volume":"42","author":"Rizzoli","year":"2008","journal-title":"Bone"},{"issue":"10","key":"2023061601040770500_dgad035-B30","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023061601040770500_dgad035-B31","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jormas.2020.03.003","article-title":"Bisphosphonate-related osteonecrosis of the jaws and dental surgery procedures in children and young people with osteogenesis imperfecta: a systematic review","volume":"121","author":"Contaldo","year":"2020","journal-title":"J Stomatol Oral Maxillofac Surg"},{"issue":"3","key":"2023061601040770500_dgad035-B32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.11138\/ccmbm\/2015.12.3.278","article-title":"An atypical fracture in male patient with osteogenesis imperfecta","volume":"12","author":"Etxebarria-Foronda","year":"2015","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"10","key":"2023061601040770500_dgad035-B33","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.4158\/EP14141.CR","article-title":"Atypical femoral fracture in an osteogenesis imperfecta patient successfully treated with teriparatide","volume":"20","author":"Holm","year":"2014","journal-title":"Endocr Pract"},{"issue":"3","key":"2023061601040770500_dgad035-B34","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1210\/jc.2012-4195","article-title":"The paradox of prevention\u2013bilateral atypical subtrochanteric fractures due to bisphosphonates in osteogenesis imperfecta","volume":"98","author":"Manolopoulos","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023061601040770500_dgad035-B35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3109\/17453674.2012.729183","article-title":"Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta\u2014a case report","volume":"83","author":"Meier","year":"2012","journal-title":"Acta Orthop"},{"issue":"5","key":"2023061601040770500_dgad035-B36","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/jbmr.3071","article-title":"Diaphyseal femur fractures in osteogenesis imperfecta: characteristics and relationship with bisphosphonate treatment","volume":"32","author":"Trejo","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023061601040770500_dgad035-B37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00198-018-4769-1","article-title":"Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series","volume":"30","author":"Andersen","year":"2019","journal-title":"Osteoporos Int"},{"issue":"19","key":"2023061601040770500_dgad035-B38","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"2023061601040770500_dgad035-B39","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2023061601040770500_dgad035-B40","author":"Grafe","year":"2018"},{"issue":"5","key":"2023061601040770500_dgad035-B41","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2023061601040770500_dgad035-B42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","article-title":"Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study","volume":"14","author":"Leali","year":"2017","journal-title":"Clin Cases Miner Bone Metab"},{"key":"2023061601040770500_dgad035-B43","author":"Ralston"},{"issue":"12","key":"2023061601040770500_dgad035-B44","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3390\/jcm7120479","article-title":"Efficacy and safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis-case series","volume":"7","author":"Kobayashi","year":"2018","journal-title":"J Clin Med"},{"issue":"13","key":"2023061601040770500_dgad035-B45","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"issue":"14","key":"2023061601040770500_dgad035-B46","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"2023061601040770500_dgad035-B47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"2023061601040770500_dgad035-B48","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"7","key":"2023061601040770500_dgad035-B49","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men","volume":"374","author":"Snyder","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2023061601040770500_dgad035-B50","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial","volume":"177","author":"Snyder","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"15","key":"2023061601040770500_dgad035-B51","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2023061601040770500_dgad035-B52","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/mrcr\/rxab018","article-title":"Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: a case report","volume":"6","author":"Uehara","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"key":"2023061601040770500_dgad035-B53","author":"Glorieux"},{"issue":"6","key":"2023061601040770500_dgad035-B54","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat Med"},{"issue":"7","key":"2023061601040770500_dgad035-B55","doi-asserted-by":"publisher","first-page":"e152571","DOI":"10.1172\/JCI152571","article-title":"Targeting TGF-\u03b2 for treatment of osteogenesis imperfecta","volume":"132","author":"Song","year":"2022","journal-title":"J Clin Invest"},{"issue":"8","key":"2023061601040770500_dgad035-B56","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","article-title":"Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta","volume":"23","author":"Lindahl","year":"2015","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"2023061601040770500_dgad035-B57","first-page":"1","article-title":"Muscle abnormalities in osteogenesis imperfecta","volume":"17","author":"Veilleux","year":"2017","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"2","key":"2023061601040770500_dgad035-B58","first-page":"171","article-title":"Physical activity in youth with osteogenesis imperfecta type I","volume":"15","author":"Pouliot-Laforte","year":"2015","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"2","key":"2023061601040770500_dgad035-B59","doi-asserted-by":"crossref","first-page":"E356","DOI":"10.1210\/jc.2013-3209","article-title":"Muscle anatomy and dynamic muscle function in osteogenesis imperfecta type I","volume":"99","author":"Veilleux","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023061601040770500_dgad035-B60","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bone.2015.05.019","article-title":"The functional muscle-bone unit in patients with osteogenesis imperfecta type I","volume":"79","author":"Veilleux","year":"2015","journal-title":"Bone"},{"issue":"5","key":"2023061601040770500_dgad035-B61","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/ajmg.a.62658","article-title":"Patient-reported prevalence of gastrointestinal issues in the adult skeletal dysplasia population with a concentration on osteogenesis imperfecta","volume":"188","author":"LoTurco","year":"2022","journal-title":"Am J Med Genet A"},{"issue":"6","key":"2023061601040770500_dgad035-B62","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023061601040770500_dgad035-B63","doi-asserted-by":"publisher","first-page":"174409","DOI":"10.1016\/j.ejphar.2021.174409","article-title":"Abaloparatide: a review of preclinical and clinical studies","volume":"909","author":"Brent","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"2023061601040770500_dgad035-B64","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"2023061601040770500_dgad035-B65","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"issue":"3","key":"2023061601040770500_dgad035-B66","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","article-title":"International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates","volume":"28","author":"Diez-Perez","year":"2017","journal-title":"Osteoporos Int"},{"issue":"4","key":"2023061601040770500_dgad035-B67","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/jbmr.3355","article-title":"Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression","volume":"33","author":"Bauer","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2023061601040770500_dgad035-B68","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023061601040770500_dgad035-B69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2023061601040770500_dgad035-B70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1210\/jc.2010-2704","volume":"96","author":"Ross","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2023061601040770500_dgad035-B71","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2202106","article-title":"Supplemental vitamin D and incident fractures in midlife and older adults","volume":"387","author":"LeBoff","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2023061601040770500_dgad035-B72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1809944","article-title":"Vitamin D supplements and prevention of cancer and cardiovascular disease","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"2023061601040770500_dgad035-B73","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1210\/jc.2011-1480","article-title":"Predictors and correlates of vitamin D status in children and adolescents with osteogenesis imperfecta","volume":"96","author":"Edouard","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023061601040770500_dgad035-B74","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.bonr.2018.04.009","article-title":"Adults with osteogenesis imperfecta: clinical characteristics of 151 patients with a focus on bisphosphonate use and bone density measurements","volume":"8","author":"Scheres","year":"2018","journal-title":"Bone Rep"},{"issue":"2","key":"2023061601040770500_dgad035-B75","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11845-013-0995-x","article-title":"Osteogenesis imperfecta in adults: phenotypic characteristics and response to treatment in an Irish cohort","volume":"183","author":"O'Sullivan","year":"2014","journal-title":"Ir J Med Sci"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad035\/49121619\/dgad035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/7\/1787\/50604856\/dgad035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/7\/1787\/50604856\/dgad035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T02:06:17Z","timestamp":1686881177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/7\/1787\/6993462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":75,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,1,20]]},"published-print":{"date-parts":[[2023,6,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad035","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,1,20]]}}}